Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Eli Lilly plans to submit a Biologics License Application (BLA) for Retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. Eli Lilly stated that Retatrutide achieved significant weight loss results and met its primary endpoint in phase III trials. (Bloomberg)

Eli Lilly plans to submit a Biologics License Application (BLA) for Retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. Eli Lilly stated that Retatrutide achieved significant weight loss results and met its primary endpoint in phase III trials. (Bloomberg)

智通财经智通财经2026/07/23 11:46
Show original
Eli Lilly plans to submit a Biologics License Application (BLA) for Retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. Eli Lilly stated that Retatrutide achieved significant weight loss effects and reached its primary endpoint in Phase III trials. (Bloomberg).
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!